Measuring bronchodilation in COPD clinical trials

Z. L. Borrill, C. M. Houghton, J. Vestbo, A. Woodcock, D. Singh (Manchester, United Kingdom)

Source: Annual Congress 2004 - COPD: insights from structure and function
Session: COPD: insights from structure and function
Session type: Thematic Poster Session
Number: 830
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Z. L. Borrill, C. M. Houghton, J. Vestbo, A. Woodcock, D. Singh (Manchester, United Kingdom). Measuring bronchodilation in COPD clinical trials. Eur Respir J 2004; 24: Suppl. 48, 830

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Year: 2006

ArtiQ.QC facilitates spirometry quality control in asthma and COPD clinical trials
Source: Virtual Congress 2021 – Future advances in respiratory physiology
Year: 2021


Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
Source: ERJ Open Res, 5 (4) 00136-2019; 10.1183/23120541.00136-2019
Year: 2019



Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials
Source: Eur Respir J 2001; 18: Suppl. 33, 331s
Year: 2001

Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

The utility of tiotropium among patients with chronic obstructive pulmonary disease (COPD): An updated meta-analysis of randomized controlled trials
Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care
Year: 2013


Safety of formoterol in asthma clinical trials
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012


Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trials
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study
Source: Eur Respir J 2014; 43: 1599-1609
Year: 2014



Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014

A multi-centre, randomised controlled trial of positive expiratory pressure mask therapy for inpatients with acute exacerbations of COPD and sputum expectoration
Source: Annual Congress 2013 –Rehabilitation, exercise and adjunct physiotherapy techniques in different respiratory conditions
Year: 2013



Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI
Source: Virtual Congress 2020 – New imaging techniques applied to old problems
Year: 2020